Drug identity, approved indication, and sources of sedation
Trazodone is an antidepressant with serotonin-reuptake-inhibiting and 5-HT2-receptor-antagonist activity. The current United States label for immediate-release oral tablets approves it for major depressive disorder in adults, not for insomnia. It also antagonizes alpha-1 adrenergic receptors and has pharmacologic effects that can cause somnolence. Sedation, dizziness, and orthostatic hypotension may therefore be perceived as bedtime effects while also creating harm. Being commonly prescribed for sleep does not make trazodone a purpose-approved sleeping pill, establish durable benefit, or make it safe for everyone.
Using lower-dose trazodone for insomnia is an off-label practice and may occur in people with depression, anxiety, or other conditions. The goals and dose ranges of antidepressant treatment and insomnia treatment are not interchangeable, and formulations or labeling can differ by product and country. A decision to use it should reflect the insomnia pattern, coexisting illness, concurrent medicines, and individual hazards. It should not be borrowed, split, or adjusted according to another person's experience.
Insomnia evidence, guideline disagreement, and cause assessment
Pooled randomized trials suggest improvement in selected measures of sleep quality and continuity, such as fewer nocturnal awakenings, less wake time after sleep onset, and roughly half an hour more objectively measured total sleep time on average. Effects on subjective total sleep time, sleep onset, sleep efficiency, and daytime impairment are smaller or inconsistent. Studies mix different causes of sleep disturbance, doses, durations, and combined therapies; confidence in many outcomes is limited. Adverse effects and withdrawals because of adverse effects occur more often than with placebo, so a group average does not predict an individual's net benefit.
The American Academy of Sleep Medicine guideline for drug treatment of chronic insomnia in adults makes a weak suggestion against using trazodone, based largely on one older, small, short trial. That does not prove that it can never help an individual, but it shows why popularity is not equivalent to strong evidence. Chronic insomnia generally warrants cognitive behavioral therapy for insomnia as first-line or parallel care and assessment of sleep opportunity, schedule, sleep apnea, restless legs, pain, nocturia, substance use, mania, and other medicines. Success should include nighttime sleep, daytime function, and harms rather than simply feeling more sedated.
Administration, food effects, and metabolic variability
Trazodone must be used according to the exact product label and prescription. The current United States antidepressant-tablet label instructs administration shortly after a meal or light snack. Food increases total absorption, lowers the peak concentration, and delays the peak from about one hour while fasting to about two hours when fed. Timing and dose for off-label insomnia use should be set by the prescriber in light of next-day obligations. A person should not redose after waking during the night, double a missed or uncertain dose, or escalate after several ineffective nights without clinical direction.
Trazodone is metabolized mainly through CYP3A4 and produces the active metabolite meta-chlorophenylpiperazine. Strong CYP3A4 inhibitors can substantially increase exposure and arrhythmia risk, whereas inducers can lower exposure. Age, hepatic or renal status, concurrent drugs, and formulation differences can all alter the practical effect. Milligram strength is not a universal measure of “sleep power,” and tablet counts cannot be converted directly among trazodone products, other antidepressants, or hypnotics with different release characteristics.
Somnolence, orthostatic hypotension, and falls
Common adverse effects include drowsiness, fatigue, dizziness or light-headedness, blurred vision, dry mouth, constipation, and nausea. Trazodone can impair judgment, reaction time, and motor coordination. Until the personal response is known, the patient should not drive, cycle, work at height, operate machinery, or perform caregiving that requires sustained alertness. Alcohol, opioids, benzodiazepines, sedating antihistamines, cannabis, and other central nervous system depressants can compound sedation and respiratory or behavioral risk.
Alpha-1 blockade can cause a blood-pressure drop on standing, palpitations, syncope, and falls; antihypertensive medicines may intensify the problem. When rising at night, sit up first, confirm alertness, stand slowly, and keep the route illuminated. Fainting, injury, or recurrent near-fainting calls for prompt medical review. Older adults, people taking diuretics, and those who are volume depleted are also more susceptible to hyponatremia. New headache, confusion, weakness, or unsteady gait—and, in severe cases, seizure or coma—should not be dismissed as poor sleep alone.
Serotonin toxicity, cardiac rhythm, bleeding, and interactions
Combining trazodone with other serotonin-enhancing medicines can cause serotonin syndrome, with particular vigilance needed after initiation or dose increases. A combination of agitation or altered awareness, sweating, fever, unstable heart rate or blood pressure, diarrhea, and tremor, myoclonus, rigidity, or hyperreflexia needs immediate assessment. Trazodone must not be used with a monoamine oxidase inhibitor or during the specified washout interval. Linezolid and intravenous methylene blue can create similarly high-risk circumstances.
Trazodone can prolong the QT interval, and ventricular arrhythmias and torsade de pointes have been reported, including postmarketing cases at 100 mg per day or less. Prescribers need to focus on known QT prolongation, congenital long-QT syndrome, symptomatic bradycardia, low potassium or magnesium, recent myocardial infarction, significant arrhythmia history, and concurrent QT-prolonging drugs or strong CYP3A4 inhibitors. Trazodone can also increase bleeding risk. With aspirin, nonsteroidal anti-inflammatory drugs, antiplatelets, or anticoagulants, unusual bruising, black stools, vomiting blood, or bleeding that will not stop requires urgent attention.
Mood warnings, priapism, and special populations
Like other antidepressants, trazodone carries a warning about increased suicidal thoughts and behaviors in children, adolescents, and young adults, especially early in treatment or around dose changes. Sudden worsening of depression, agitation, impulsivity, unusual activation, or thoughts of self-harm require prompt contact with the treating team; imminent danger requires emergency help. Screening for bipolar disorder is important because mania or hypomania can be precipitated. Trazodone is not approved for pediatric patients, and an adult off-label sleep practice should not be extrapolated to children.
A rare but critical emergency is priapism. A painful erection or one lasting longer than four hours requires stopping further doses and immediate emergency care; delay can cause irreversible tissue injury. Sickle cell disease, multiple myeloma, leukemia, or anatomic penile abnormalities should be disclosed beforehand. Trazodone can also precipitate angle-closure glaucoma; eye pain, abrupt visual change, or colored halos around lights requires urgent evaluation. Pregnancy, lactation, older age, and hepatic or renal impairment call for individualized assessment because evidence is limited or exposure and vulnerability may differ.
Discontinuation, overdose response, and continuing reassessment
Abrupt discontinuation can produce anxiety, agitation, sleep disruption, dizziness, sensory disturbance, headache, sweating, nausea, or mood changes. After regular or longer use, tapering is generally planned with the prescriber. Trazodone is not a controlled substance, but that does not make sharing it or mixing it with alcohol and sedatives safe. Overdose can cause profound somnolence, hypotension, seizures, respiratory arrest, priapism, and dangerous electrocardiographic or rhythm changes, and there is no specific antidote. Suspected overdose requires immediate emergency or poison-center contact rather than waiting for the person to wake or inducing vomiting.
During continuing treatment, a brief record of sleep onset, awakenings, total sleep, next-day alertness, mood, and fall symptoms can support periodic review of whether benefit still exceeds harm. Chest pain, palpitations with fainting, seizure, breathing difficulty, serotonin-syndrome features, imminent self-harm risk, or persistent erection warrants emergency care. Store the medicine at the temperature specified on its label, tightly closed, protected from light, and out of children's reach; do not give leftovers to anyone else. If the apparent benefit is mainly nighttime sedation accompanied by morning slowing, low blood pressure, or reduced function, the treatment goal has not truly been met.